Sage Journals: Discover world-class research

Abstract

Background

With the growing recognition of the medical applications of hydrogen, hydrogen gas inhalers are increasingly used in clinics and other healthcare settings. However, hydrogen is highly explosive, and numerous explosion incidents involving these inhalers have been reported.

Objectives

This study evaluates the safety risks of high-concentration hydrogen inhalers (67%–99.99% v/v H₂) following multiple device explosions and a documented pulmonary explosion case, and to determine an optimal concentration balancing safety and efficacy.

Methods

We analyzed device explosion incidents recorded by the Consumer Affairs Agency of Japan and an in-body hydrogen explosion case reported in a 2024 scientific paper, and subsequently discussed the factors contributing to these accidents based on the explosive properties of hydrogen gas.

Results

High-concentration inhalers (>10% v/v H₂) pose a substantial explosion risk, as confirmed by multiple device failures reported by Japan’s Consumer Affairs Agency and a 2024 in-vivo pulmonary explosion case. Limiting hydrogen to ≤10% v/v maintains efficacy for intracellular hydroxyl radical scavenging while staying below the lower explosive limit.

Conclusion

Two critical preventable hazards exist with high-concentration hydrogen therapy: external device explosion and internal airway detonation. Immediate transition to low-concentration (≤10% v/v H₂) inhalers is strongly recommended, as they provide effective concentration while eliminating life-threatening risks, ensuring patient safety without compromising clinical outcomes.

Keywords

hydrogen gas inhalation hydrogen explosion low-concentration hydrogen therapy hydroxyl radical scavenging patient safety

Get full access to this article

View all access options for this article.

References

Ohsawa

Ishikawa

Takahashi

, et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat Med 2007; 13(6): 688–694.

Setsukinai

Urano

Kakinuma

, et al. Development of novel fluorescence probes that can reliably detect reactive oxygen species and distinguish specific species. J Biol Chem 2003; 278(5): 3170–3175.

Jomova

Raptova

Alomar

, et al. Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging, Arch Toxicol, Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging 2023; 97: 2499–2574.

Tian

Zhang

Wang

, et al. Hydrogen, a novel therapeutic molecule, regulates oxidative stress, inflammation, and apoptosis. Front Physiol 2021; 12: 1–14.

Kurokawa

Hirano

S-I

Ichikawa

, et al. Preventing explosions of hydrogen gas inhalers. Med Gas Res 2019; 9(3): 160–162.

Tian

Zhang

Wang

, et al. Hydrogen, a novel therapeutic molecule, regulates oxidative stress, inflammation, and apoptosis. Front Physiol 2021; 12: 789507.

Crowl

Y-D

. The hazards and risks of hydrogen. J Loss Prev Process Ind 2007; 20(2): 158–164.

Astbury

Hawksworth

. Spontaneous ignition of hydrogen leaks: a review of postulated mechanisms. Int J Hydrogen Energy 2007; 32(13): 2178–2185.

Tsuchikane

Yamagiwa

Takada

, et al. A case of lung injury due to a hydrogen explosion caused by the simultaneous use of two home folk remedies devices. Acute Med Surg 2024; 11(1): e70019.

10.

Sano

Shirakawa

Katsumata

, et al. Low-flow nasal cannula hydrogen therapy. J Clin Med Res 2020; 12(10): 674–680.

11.

Liu

Kurokawa

Fujino

, et al. Erratum: estimation of the hydrogen concentration in rat tissue using an airtight tube following the administration of hydrogen via various routes. Sci Rep 2015; 4(5485): 1–4.

12.

Korovljev

Trivic

Òtajer

, et al. Short-term H₂ inhalation improves cognitive function in older women: a pilot study. Int J Gerontol 2020; 14(2): 149–150.

13.

Hirano

Ichikawa

Sato

, et al. Successful treatment of myalgic encephalomyelitis/chronic fatigue syndrome using hydrogen gas: four case reports. Med Gas Res 2024; 14(2): 84–86.

14.

Okada

Ogawa

Takagi

, et al. A double-blinded, randomized controlled clinical trial of hydrogen inhalation therapy for idiopathic sudden sensorineural hearing loss. Front Neurosci 2022; 16: 1–12.

15.

Tamura

Suzuki

Homma

, et al. Efficacy of inhaled hydrogen on neurological outcome following brain ischaemia during post-cardiac arrest care (HYBRID II): a multi-centre, randomised, double-blind, placebo-controlled trial. eClinicalMedicine 2023; 58(Hybrid Ii): 5–11.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.13 MB